BBI completed the acquisition of IBEX Technologies for $37.9m.

BBI, an independent manufacturer of immunodiagnostic reagents globally, completed the acquisition of IBEX Technologies, a developer and manufacturer of high-precision enzymes and diagnostic solutions, for $37.9m. “Joining the BBI family marks the beginning of a promising new chapter for IBEX, with exciting development opportunities for us and our Canadian partners on the horizon. We are eager to see the innovative solutions this partnership will bring forth,” Paul Behr, IBEX Chairman, President, and CEO.